For both adapted disease-free survival and adapted overall survival, the absolute benefit of extended aromatase inhibition increased significantly when additional high-risk factors, i.e. lymph node-positive disease and tumours of larger size, were present. The gene discussed is CYP19A1; the disease is neoplasm.